- Amgen Research Offers Clue to Weight-Loss Drug Paradox
Amgen Inc. researchers have found a clue to one of the more puzzling questions in obesity drug development: How can blocking a hormone help people lose weight when activating the same hormone appears to work, too?
Product·1 article / 1 outlet·7d ago
- Amgen Drug Shows Promise in Sjögren’s Disease Phase 3 Trial
Amgen Inc.’s experimental drug helped patients with moderate-to-severe Sjögren’s disease in a late-stage trial, advancing a potential therapy for the chronic autoimmune condition that has no approved treatment.
Product·2 articles / 2 outlets·14d ago
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that dazodalibep succeeded in the trial, following its acquisition in Amgen's buyout of Horizon Therapeutics.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen has announced positive topline results from its Phase 3 study of dazodalibep for moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown success in this clinical trial.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that the drug successfully met its primary endpoint, showcasing its potential effectiveness in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that the treatment met its primary endpoint, demonstrating efficacy in the patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The results indicate that the drug has succeeded in the pivotal trial, following its acquisition in Amgen's buyout of Horizon Therapeutics.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
- Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
Product·2 articles / 2 outlets·15d ago·◆ Primary source
